Weight loss drugs have been in demand across the globe for its advantages in controlling the extra heaviness along with other health benefits. But what happens if an individual takes a break from these drugs?
A study has found that when patients stop taking weight-loss medications, the beneficial effects of the drugs on weight and other health issues disappear within two years.
Reviewing data on 9,341 obese or overweight patients treated in 37 studies with any of 18 different weight-loss medications, researchers found they regained, on average, nearly one pound (0.4 kg) per month after stopping the drugs. They were projected to return to pre-treatment weight by 1.7 years.
The report of the study in The BMJ also mentioned that heart health risk factors, such as blood pressure and cholesterol levels that benefited from the drugs, were projected to return to pre-treatment levels within 1.4 years after stopping the medications, on average.
For your daily dose of medical news and updates, visit: HEALTH
Roughly half of the patients had taken GLP-1 medications, including 1,776 who received the newer, more effective drugs semaglutide, sold as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly, Reuters reported.
It was observed that the weight regain rate was faster with semaglutide and tirzepatide, averaging nearly 1.8 pounds (0.8 kg) per month. However, because people on semaglutide or tirzepatide initially lose more weight, they all tend to return to baseline at approximately the same time. That was roughly 1.5 years with these new drugs versus 1.7 years after stopping any of the drugs.
Regardless of how much weight was lost, monthly weight regain was faster after weight-loss drugs than after behavioral weight management programs, the researchers also found.
The retrospective study could not determine whether some patients were more likely than others to keep off the weight. "Understanding who does well and who does not is a bit of a holy grail question in weight-loss research, but nobody has the answer to that yet," said senior researcher Dimitrios Koutoukidis of Oxford University to Reuters.